Expression of the scaffold connector enhancer of kinase suppressor of Ras 1 (CNKSR1) is correlated with clinical outcome in pancreatic cancer

[1]  R. Gibbs,et al.  Genomic analyses identify molecular subtypes of pancreatic cancer , 2016, Nature.

[2]  B. Jiang,et al.  MicroRNA-497 inhibits tumor growth and increases chemosensitivity to 5-fluorouracil treatment by targeting KSR1 , 2015, Oncotarget.

[3]  B. Warscheid,et al.  Differential tyrosine phosphorylation controls the function of CNK1 as a molecular switch in signal transduction. , 2015, Biochimica et biophysica acta.

[4]  S. Ormanns,et al.  Desmogleins as prognostic biomarkers in resected pancreatic ductal adenocarcinoma , 2015, British Journal of Cancer.

[5]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[6]  I. Ellis,et al.  KSR1 regulates BRCA1 degradation and inhibits breast cancer growth , 2014, Oncogene.

[7]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[8]  D. Morrison,et al.  EphrinB1 Interacts with CNK1 and Promotes Cell Migration through c-Jun N-terminal Kinase (JNK) Activation* , 2014, The Journal of Biological Chemistry.

[9]  Chuay-Yeng Koo,et al.  The dual function of KSR1: a pseudokinase and beyond. , 2013, Biochemical Society transactions.

[10]  Y. Yatabe,et al.  Prognostic value of K-ras mutation status and subtypes in endoscopic ultrasound-guided fine-needle aspiration specimens from patients with unresectable pancreatic cancer , 2013, Journal of Gastroenterology.

[11]  T. Fehm,et al.  Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. , 2013, Human pathology.

[12]  L. Qin,et al.  A Novel Survival-Based Tissue Microarray of Pancreatic Cancer Validates MUC1 and Mesothelin as Biomarkers , 2012, PloS one.

[13]  Leandro Martínez,et al.  Medium Chain Fatty Acids Are Selective Peroxisome Proliferator Activated Receptor (PPAR) γ Activators and Pan-PPAR Partial Agonists , 2012, PloS one.

[14]  D. Morrison,et al.  RAF Inhibitor-Induced KSR1/B-RAF Binding and Its Effects on ERK Cascade Signaling , 2011, Current Biology.

[15]  Robert E. Lewis,et al.  KSR1 is overexpressed in endometrial carcinoma and regulates proliferation and TRAIL-induced apoptosis by modulating FLIP levels. , 2011, The American journal of pathology.

[16]  P. Spellman,et al.  Subtypes of Pancreatic Ductal Adenocarcinoma and Their Differing Responses to Therapy , 2011, Nature Medicine.

[17]  G. Radziwill,et al.  CNK1 is a novel Akt interaction partner that promotes cell proliferation through the Akt-FoxO signalling axis , 2010, Oncogene.

[18]  G. Radziwill,et al.  CNK1 Promotes Invasion of Cancer Cells through NF-κB–Dependent Signaling , 2010, Molecular Cancer Research.

[19]  S. Altekruse,et al.  Associations between selected biomarkers and prognosis in a population-based pancreatic cancer tissue microarray. , 2009, Cancer research.

[20]  G. Parmigiani,et al.  Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses , 2008, Science.

[21]  Jeffrey E. Lee,et al.  Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  T. Khoury,et al.  Epithelial-Mesenchymal Transition (EMT) and Activated Extracellular Signal-regulated Kinase (p-Erk) in Surgically Resected Pancreatic Cancer , 2007, Annals of Surgical Oncology.

[23]  D. Morrison,et al.  Integrating signals from RTKs to ERK/MAPK , 2007, Oncogene.

[24]  D. Choi,et al.  Impact of epidermal growth factor receptor (EGFR) kinase mutations, EGFR gene amplifications, and KRAS mutations on survival of pancreatic adenocarcinoma , 2007, Cancer.

[25]  T. Khoury,et al.  Activated Akt and Erk Expression and Survival After Surgery in Pancreatic Carcinoma , 2006, Annals of Surgical Oncology.

[26]  W. Kolch.  Coordinating ERK/MAPK signalling through scaffolds and inhibitors , 2005, Nature Reviews Molecular Cell Biology.

[27]  M. Kattan,et al.  Validation of a postresection pancreatic adenocarcinoma nomogram for disease-specific survival. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  Robert E. Lewis,et al.  Expression of kinase suppressor of Ras1 enhances cisplatin-induced extracellular signal-regulated kinase activation and cisplatin sensitivity. , 2005, Cancer research.

[29]  Murray F. Brennan,et al.  Prognostic Nomogram for Patients Undergoing Resection for Adenocarcinoma of the Pancreas , 2004, Annals of surgery.

[30]  R. Xavier,et al.  The Scaffold Protein CNK1 Interacts with the Tumor Suppressor RASSF1A and Augments RASSF1A-induced Cell Death* , 2004, Journal of Biological Chemistry.

[31]  A. Jemal,et al.  Cancer statistics, 2016 , 2016, CA: a cancer journal for clinicians.

[32]  C. Yeo,et al.  Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer , 2013, Journal of surgical oncology.

[33]  F. Bosman,et al.  WHO Classification of Tumours of the Digestive System , 2010 .

[34]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.